Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

The conversation is about expecting results from Breezula, a hair loss treatment, with no new information released as of April 1st. Some joked it's just onion juice, while another comment suggested a conspiracy to cause baldness.

The conversation humorously discusses inducing goosebumps to potentially reverse hair loss, with mentions of using cold therapy and muscle exercises. It also references other unconventional ideas like removing a testicle to lower DHT.

Topical spironolactone is discussed as a hair loss treatment, with concerns about its effectiveness and side effects compared to finasteride and minoxidil. Users mention its unpleasant smell, potential systemic absorption, and suggest alternatives like pyrilutamide and alfatradiol.

The conversation discusses skepticism about a new hair loss treatment called project K, which claims to replicate a chemical from UCLA research but is suspected to be a scam. The original poster plans to continue using oral minoxidil, finasteride, and dutasteride, along with microneedling, for hair regrowth.

Some users believe John Harper's hair regrowth claims using dermarolling, coffee, and oils are misleading, while others defend his methods. The conversation highlights skepticism about alternative treatments and emphasizes finasteride, dutasteride, and minoxidil as proven solutions for hair loss.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

A person mistakenly drank an entire bottle of topical minoxidil, leading to ICU admission with shock and heart failure. The incident highlights the dangers of ingesting topical treatments and the importance of proper usage and dosage.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

A sugar gel was claimed to trigger hair regrowth, but users reported no results and potential cancer risks. The discussion included comparisons to minoxidil and skepticism about the effectiveness of the sugar treatment.

A user describes using a Dermastamp for microneedling their scalp, noting a crunching sound when pressing it firmly. Another user suggests the crunching might be from breaking up scalp calcification.

Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.

A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

Exosome therapy for hair loss is questioned for its effectiveness and authenticity. Users express skepticism, citing manipulated photos and high costs.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

The conversation discusses a user's experiment of "burning the scalp" to treat hair loss, with mixed opinions on its effectiveness. Some suggest returning to proven treatments like finasteride and minoxidil, while others note slight improvements in hair density.

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.

A user's transformation due to their efforts in fighting hair loss, which was achieved without a hair transplant; the discussion includes advice about treatments such as minoxidil and finasteride.

The conversation discusses the use of RU58841 for hair loss, with concerns about its legality in Germany and potential legal consequences. Alternatives like finasteride and dutasteride are mentioned, with some users questioning the effectiveness and safety of RU58841.

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.

The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.

Chris Bumstead got a hair transplant at Now Hair Time, and the discussion focuses on why he chose a less reputable clinic despite having the means for a better one, with some suggesting it was for financial gain. The conversation also touches on concerns about the naturalness of the hairline and the potential impact of his steroid use on the transplant's success.